Welcome to our dedicated page for Mindset Pharma news (Ticker: MSSTF), a resource for investors and traders seeking the latest updates and insights on Mindset Pharma stock.
Mindset Pharma Inc. is a drug discovery company that focuses on developing novel psychedelic and non-psychedelic medications to address neuropsychiatric and neurological disorders with unmet medical needs. The company recently entered into a definitive arrangement agreement with Otsuka Pharmaceutical Co., Ltd., signaling a significant acquisition worth approximately CAD $80 million. Mindset's innovative compounds and synthesis processes aim to revolutionize the treatment of psychiatric disorders, contributing to patient care on a global scale.
The Transaction, expected to close in October 2023, marks a strategic move by Otsuka to strengthen its presence in the psychiatry and neurology therapeutic areas. Mindset's shareholders will benefit from the all-cash acquisition, demonstrating a premium value of $0.75 per share. With a focus on maximizing the value of its assets and IP portfolio, Mindset's collaboration with Otsuka is poised to lead to groundbreaking advancements in patient treatment.
In pursuit of its mission to develop next-generation pharmaceutical assets, Mindset is dedicated to creating optimized and patentable psychedelic medicines, leveraging the therapeutic potential of psychedelic drugs. Through proprietary compounds, novel families of psychedelic compounds, and innovative synthesis processes, the company is at the forefront of advancing treatment options for neurological and psychiatric conditions.
Mindset Pharma Inc. (OTCQB: MSSTF) has announced an exclusive licensing agreement with Cybin Inc. for a subset of its preclinical compounds, excluding its lead candidate MSP-1014. The deal includes a $500,000 initial payment and potential milestone payments totaling up to $9.5 million based on successful drug development. Additionally, Mindset is set to receive a 2% royalty on sales of licensed products. This agreement supports Mindset's strategy of advancing its psychedelic treatments, enhancing its partnerships in the drug development space.
Mindset Pharma Inc. (CSE: MSET, OTCQB: MSSTF) announced on September 14, 2022, that it has received favorable Scientific Advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its Phase 1 clinical trial of MSP-1014, its lead psychedelic drug candidate aimed at treating Major Depressive Disorders (MDD). The MHRA confirmed that no additional preclinical studies are required at this stage, and provided guidance on clinical trial design, dosing, and patient selection. MSP-1014 has shown improved efficacy and safety profiles in preclinical studies, prompting its advancement to human trials.
Mindset Pharma Inc. (OTCQB: MSSTF) has filed 16 international patent applications for its Family 1 psychedelic drugs, including its lead candidate, MSP-1014. This second-generation psilocybin analog is expected to be more effective and safer than existing treatments. The company aims to start human clinical trials in 2023, enhancing its intellectual property protection strategy. Additionally, Mindset has issued options for 200,000 common shares at $0.55 each.
Mindset Pharma (OTCQB: MSSTF) announced the development of three new families of novel, non-tryptamine psychedelic compounds as part of its ongoing drug discovery efforts. These compounds aim to address unmet medical needs in neuropsychiatric and neurological disorders. Utilizing a fragment-based drug discovery method, Mindset has filed provisional patents on these families, showing promising pre-clinical results in functional potency and CNS penetration. This advancement expands Mindset's research and development portfolio, enhancing its intellectual property and potential drug efficacy.
Mindset Pharma Inc. (OTCQB: MSSTF) announced participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, at the Lotte New York Palace Hotel. CEO James Lanthier and CSO Joseph Araujo will engage in a fireside chat on September 13 at 9:30 a.m. ET. The company focuses on developing next-generation psychedelic and non-psychedelic medications aimed at treating neuropsychiatric disorders. Attendees can register for the event and schedule one-on-one meetings through H.C. Wainwright representatives.
Mindset Pharma (CSE: MSET) has released a letter to shareholders highlighting significant advancements in its drug development strategy for psychedelic medications targeting neuropsychiatric disorders. The company has introduced a novel intranasal formulation technology, showing enhanced pharmacokinetics for 5-MeO-DMT. Collaborations with Clerkenwell Health and the Centre for Addiction and Mental Health are set to support clinical trials for MSP-1014, a psilocybin-like candidate. The U.S. Patent and Trademark Office recently granted allowance for several patent applications, underscoring Mindset's robust intellectual property position.
Mindset Pharma Inc. (OTCQB: MSSTF) announced that its patent application, 17/387,864, has been allowed by the USPTO. This patent covers 3-Pyrrolidine-Indole derivatives, novel analogs of psilocybin. The compounds show improved pharmacokinetics and pharmacodynamics. Collaborative efforts with the McQuade Center for Strategic Research and Development (MSRD) are ongoing to advance these drug candidates to clinical trials. CEO James Lanthier emphasized the strong IP position and potential benefits of their Family 2 compounds in treating CNS disorders.
Mindset Pharma Inc. (OTCQB: MSSTF) announced the development of a novel, patent-pending intranasal formulation technology aimed at enhancing the delivery of psychedelic medicines for CNS disorders. This technology improves CNS penetration of 5-MeO-DMT by a factor of three compared to standard formulations. The CEO emphasized the potential for reduced dosages and faster uptake, ultimately leading to safer treatments. A PCT application was filed on May 26, 2022, marking a significant step in Mindset's innovation pipeline.
Mindset Pharma Inc. (OTCQB: MSSTF) has announced a research collaboration with the Centre for Addiction and Mental Health (CAMH) to explore its lead asset, MSP-1014, a second-generation psilocybin-like compound. The study aims to investigate how various doses of psychedelic compounds influence molecular biomarkers of brain plasticity. Led by Dr. Anh Dzung Lê, the research will provide insights into the effects of MSP-1014 compared to psilocybin. CEO James Lanthier expressed excitement for the collaboration, highlighting its potential to advance mental health treatment.
Mindset Pharma (OTCQB: MSSTF) has received a Notice of Allowance from the USPTO for its patent application 17/387,845, focused on psilocin derivatives as psychedelic agents for CNS disorders. This patent, with a priority date of February 4, 2020, covers several second-generation drug candidates classified as 'Family 1,' which aim to improve pharmacokinetics and safety over existing treatments like psilocybin. CEO James Lanthier highlighted this milestone as a step towards strengthening the company's intellectual property and pipeline growth.
FAQ
What is the market cap of Mindset Pharma (MSSTF)?
What is Mindset Pharma Inc. focused on?
What recent agreement did Mindset Pharma Inc. enter into?
How will the acquisition benefit Mindset Pharma Inc.'s shareholders?
What is the focus of Mindset Pharma Inc.'s drug development programs?
What is the expected timeline for the completion of the Transaction between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd.?
How does the collaboration between Mindset Pharma Inc. and Otsuka Pharmaceutical Co., Ltd. contribute to patient care?
What sets Mindset Pharma Inc. apart in the pharmaceutical industry?
